1. |
Ukor IF, Walley KR. Vasopressin in vasodilatory shock. Crit Care Clin, 2019, 35(2): 247-261.
|
2. |
Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. Crit Care, 2011, 15(4): 226.
|
3. |
McIntyre WF, Um KJ, Alhazzani W, et al. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA, 2018, 319(18): 1889-1900.
|
4. |
Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology, 2017, 126(1): 85-93.
|
5. |
Xiao X, Zhang J, Wang Y, et al. Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res, 2016, 200(1): 274-282.
|
6. |
Hammond DA, Ficek OA, Painter JT, et al. Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy, 2018, 38(5): 531-538.
|
7. |
Honarmand K, Um KJ, Belley-Côté EP, et al. Canadian critical care society clinical practice guideline: the use of vasopressin and vasopressin analogues in critically ill adults with distributive shock. Can J Anaesth, 2020, 67(3): 369-376.
|
8. |
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ, 2004, 328(7454): 1490.
|
9. |
Barzegar E, Ahmadi A, Mousavi S, et al. The therapeutic role of vasopressin on improving lactate clearance during and after vasogenic shock: microcirculation, is it the black box? Acta Med Iran, 2016, 54(1): 15-23.
|
10. |
Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation, 2003, 107(18): 2313-2319.
|
11. |
Hajjar LA, Zambolim C, Belletti A, et al. Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the vancs ii randomized clinical trial. Crit Care Med, 2019, 47(12): 1743-1750.
|
12. |
Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology, 2002, 96(3): 576-582.
|
13. |
Lauzier F, Lévy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med, 2006, 32(11): 1782-1789.
|
14. |
Malay MB, Ashton RC Jr, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma, 1999, 47(4): 699-703.
|
15. |
Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care, 2009, 13(4): R130.
|
16. |
Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med, 2008, 358(9): 877-887.
|
17. |
Fonseca-Ruiz N, Lemos Cano A, Ortiz Carmona DP, et al. Uso de vasopresina en pacientes con choque séptico refractario a catecolaminas (Spanish). Acta Colombiana de Cuidado Intensivo, 2013, 13(2): 114-123.
|
18. |
Oliveira S, Dessa F, Rocha C, et al. Early vasopressin application in shock study. Crit Care, 2014, 18(S1): 158.
|
19. |
Abdullah MH, Saleh SM, Morad WS. Terlipressin versus norepinephrine to counteract intraoperative paracentesis induced refractory hypotension in cirrhotic patients. Egypt J Anaes, 2012, 28(1): 29-35.
|
20. |
Acevedo JG, Fernandez J, Escorsell A, et al. Clinical efficacy and safety of terlipressin administration in cirrhotic patients with septic shock. J Hepatol, 2009, 50: S73.
|
21. |
Albanèse J, Leone M, Delmas A, et al. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med, 2005, 33(9): 1897-1902.
|
22. |
陈志, 周萍, 卢院华, 等. 去甲肾上腺素与特利加压素对ARDS合并感染性休克患者影响的比较: 一项前瞻性单盲随机对照研究. 中华危重病急救医学, 2017, 29(2): 111-116.
|
23. |
Choudhury A, Kedarisetty CK, Vashishtha C, et al. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int, 2017, 37(4): 552-561.
|
24. |
Hua F, Wang X, Zhu L. Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. J Emerg Med, 2013, 44(2): 434-439.
|
25. |
Svoboda P, Scheer P, Kantorová I, et al. Terlipressin in the treatment of late phase catecholamine-resistant septic shock. Hepatogastroenterology, 2012, 59(116): 1043-1047.
|
26. |
Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med, 2018, 44(11): 1816-1825.
|
27. |
Prakash V, Choudhury AK, Sarin SK. Early introduction of a combination of low dose terlipressin and noradrenaline as vasopressors is superior to high dose noradrenaline alone in patients of cirrhosis with septic shock (NCT02468063). Hepatology, 2017: 138A.
|
28. |
Russell JA, Vincent JL, Kjølbye AL, et al. Selepressin, a novel selective vasopressin V. Crit Care, 2017, 21(1): 213.
|
29. |
韩旭东, 孙华, 黄晓英, 等. 垂体后叶素与去甲肾上腺素治疗感染性休克比较的临床研究. 中国危重病急救医学, 2012, 24(1): 33-37.
|
30. |
Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA, 2016, 316(5): 509-518.
|
31. |
Wetterslev M, Haase N, Hassager C, et al. New-onset atrial fibrillation in adult critically ill patients: a scoping review. Intensive Care Med, 2019, 45(7): 928-938.
|
32. |
Kim K, Yang PS, Jang E, et al. Long-term impact of newly diagnosed atrial fibrillation during critical care: a South Korean nationwide cohort study. Chest, 2019, 156(3): 518-528.
|
33. |
Walkey AJ, Wiener RS, Ghobrial JM, et al. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA, 2011, 306(20): 2248-2254.
|
34. |
Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med, 2019, 45(6): 844-855.
|
35. |
Reardon DP, DeGrado JR, Anger KE, et al. Early vasopressin reduces incidence of new onset arrhythmias. J Crit Care, 2014, 29(4): 482-485.
|
36. |
Hammond DA, Cullen J, Painter JT, et al. Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock. J Intensive Care Med, 2019, 34(11-12): 910-916.
|
37. |
Wu JY, Stollings JL, Wheeler AP, et al. Efficacy and outcomes after vasopressin guideline implementation in septic shock. Ann Pharmacother, 2017, 51(1): 13-20.
|
38. |
Bauer SR, Sacha GL, Reddy AJ. Mortality, morbidity, and costs after implementation of a vasopressin guideline in medical intensive care patients with septic shock: an interrupted time series analysis. Ann Pharmacother, 2020, 54(4): 314-321.
|
39. |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med, 2017, 45(3): 486-552.
|
40. |
Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One, 2015, 10(8): e0129305.
|
41. |
Huang P, Guo Y, Li B, et al. Terlipressin versus norepinephrine for septic shock: a systematic review and meta-analysis. Front Pharmacol, 2019, 10: 1492.
|
42. |
Williams MD, Russell JA. Terlipressin or norepinephrine in septic shock: do we have the answer? J Thorac Dis, 2019, 11(Suppl 9): S1270-S1273.
|
43. |
Bredhold BE, Winters SD, Callison JC Jr, et al. Impact of the sequence of norepinephrine and vasopressin discontinuation in patients recovering from septic shock. Hosp Pharm, 2020, 55(1): 26-31.
|
44. |
Wu Z, Zhang S, Xu J, et al. Norepinephrine vs vasopressin: which vasopressor should be discontinued first in septic shock? A meta-analysis. Shock, 2020, 53(1): 50-57.
|
45. |
Hammond DA, Sacha GL, Bissell BD, et al. Effects of norepinephrine and vasopressin discontinuation order in the recovery phase of septic shock: a systematic review and individual patient data meta-analysis. Pharmacotherapy, 2019, 39(5): 544-552.
|
46. |
Lam SW, Barreto EF, Scott R, et al. Cost-effectiveness of second-line vasopressors for the treatment of septic shock. J Crit Care, 2020, 55: 48-55.
|
47. |
Laterre PF, Berry SM, Blemings A, et al. Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: the SEPSIS-ACT randomized clinical trial. JAMA, 2019, 322(15): 1476-1485.
|
48. |
Kunkes JH, Baker WL, Hammond JA, et al. Vasopressin therapy in cardiac surgery. J Card Surg, 2019, 34(1): 20-27.
|